<DOC>
	<DOCNO>NCT02604498</DOCNO>
	<brief_summary>This single center , open-label , non-randomized , 1:1 parallel control single dose administration study design . Healthy subject match moderate hepatic function impair ( Child-Pugh B，7-9 ) subject age , gender weight parallel control , match healthy normal hepatic function accord subject impaired hepatic function , enrollment subject moderate impair hepatic function ( Child-Pugh B，7-9 ) . Hepatic function impair group control group receive orally single-dose nemonoxacin malate capsule ( 0.5g ) . Collect blood urine sample administration perform pharmacokinetic analysis safety observation .</brief_summary>
	<brief_title>Pharmacokinetics Study Nemonoxacin Malate Capsules Subjects With Moderate Impaired Hepatic Function</brief_title>
	<detailed_description>Single dose study : evaluate safety tolerability oral nemonoxacin capsule 500mg .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Subjects hepatic impairment 1. male female age 18 70 years； 2. body mass index 17 30 kg/m2； 3. eGRF＞50ml/min/1.73m2； 4 . Patients stable condition moderate impair hepatic function , due viral hepatitis , alcoholic liver disease , autoimmune hepatitis , primary biliary cirrhosis cause , determine level B accord ChildPugh classification； 5 . Bultrasonography , CT MRI show biopsy confirm positive diagnosis cirrhosis ； 6 . Has stable regimen treatment hepatic function impair 3 month prior enrollment ; 7 . Female volunteer must meet : 1 . Has sterilization operation , postmenopausal must postmenopausal &gt; 1 year , 2 . Has childbearing potential , meet requirement follow : Negative pregnancy test prior enrollment , Agree use 1 medical accept method birth control ( eg . Hormonal contraceptive , barrier contraceptive additional spermicide , intrauterine device ) whole study continue 1 month end study , Nonbreastfeeding ; 8 . Male volunteer must agree use medical accept method birth control ( e.g . barrier contraceptive sexual partner use method ( 7 ) ) study 1month end study； 9 . Agree stay ward prior dose within 48h , agree take coffee , tea , chocolate , alcohol , grapefruit juice , orange juice food drink contain caffeine xanthine； 10 . Can sign informed consent form accord； 11 . Can comply study procedure Healthy subject without hepatic impairment 1 . Male female volunteer ( match subject hepatic impairment gender）； 2 . Aged 18 70 year ( match subject hepatic impairment±5 year , match range exceed±5 year ) ； 3 . Has body mass index 17 30 kg/m2（matched subject hepatic impairment±15 % ，matched range exceed±15 % ）； 4 . Must good health determine screen medical history , physical examination , vital sign , laboratory test , B ultrasonography chest X ray； 5 . Female volunteer must meet : 1 . Has sterilization operation , postmenopausal must postmenopausal &gt; 1 year , 2 . Has childbearing potential , meet requirement follow : Negative pregnancy test prior enrollment , Agree use 1 medical accept method birth control ( eg . Hormonal contraceptive , barrier contraceptive additional spermicide , intrauterine device ) whole study continue 1month end study , Nonbreastfeeding； 6 . Male volunteer must agree use medical accept method birth control ( e.g . barrier contraceptive sexual partner use method ( 7 ) ) study 1month end study； 7 . Agree stay ward prior dose within 48h , agree take coffee , tea , chocolate , alcohol , grapefruit juice , orange juice food drink contain caffeine xanthine； 8 . Can sign informed consent form accord； 9 . Can comply study procedure Subjects hepatic impairment 1 . Has know suspect allergy quinolones , fluoroquinolones , Nemonoxacin excipients allergic constitution； 2 . Has acute disease chronic disease may affect PK profile drug vivo except disease cause hepatic function impaired； 3 . Has abnormal result laboratory test clinical significance except caused disease hepatic function impaired； 4 . Has history clinically significant cardiovascular , neurological psychiatric , gastrointestinal , pulmonary , renal , endocrine disease prior study within 1 year； 5 . Has disease seriously affect immune system hematological disease , malignant tumor , take immunosuppressant； 6 . Has acute subacute hepatic function failure； 7 . Has experience esophageal variceal bleeding within past 6 months； 8 . Has advance ascites spontaneous bacterial peritonitis； 9 . Has history Gilbert 's disease； 10 . Has resistance liver function abnormal orally take nucleoside analogue , antiviral drug； 11 . Stop take nucleoside analogue , antiviral drug within 1 year； 12 . Has total bilirubin＞3×upper limit normal ( ULN ) without cholestasis ; alkaline phosphatase ( ALP ) ＞2×ULN； 13 . Alanine Aminotransferase ( ALT ) Aspartate Aminotransferase（AST）＞5×ULN； 14 . ALT AST＞3×ULN total bilirubin＞2×ULN； 15. international senstibity index，INR≥1.5 prothrombin time activity≤40 % ； 16 . ChildPugh assess C level； 17 . Has history alcoholism within 2 year prior dose ; drink≥12 time within 3 month prior dose ; alcohol test positive screening； 18 . Has history drug misuse within 2 year prior dose ; urine drug screen positive； 19 . Has history take product tobacco nicotine 5 cigarettes/day within 1 month prior dose , stop smoking study ; 20 . Use another investigational drug drug damage hepatic function within 3 month prior dosing； 21 . Use drug affect function liver metabolism enzyme ( e.g . benzene , isopropyl amine , barbiturates benzodiazepine , marijuana , cocaine , opiates phencyclidine ) within 30 day prior dose ； 22 . Has take drug may affect PK profile investigate drug ( e.g . antacid , sucralfate , metal cation , calcium supplement , warfarin , nonsteroidal antiinflammatory drug , theophylline , cyclosporine , probenecid cimetidine ) ； 23 . Has gastrointestinal disease malabsorption syndrome affect drug Absorb； 24 . Has history seizures central nervous system disease investigator considers interfere compliancy protocol ; risk suicide； 25 . Clinical significant abnormal 12lead electrocardiogram ( ECGs ) screening ( eg . atrioventricular block , torsades de pointes ventricular tachycardia ( TdT ) , type ventricular tachycardia , ventricular fibrillation , ventricular flutter , T wave change clinical significance abnormal result 12lead ECG affect QTc interphase ) ； 26 . HIV syphilis RPR test positive； 27 . Conditions investigator consider suitable enrol study . Healthy subject without hepatic impairment 1 . Has know suspect allergy quinolones , fluoroquinolones , nemonoxacin excipients allergic constitution； 2 . Has history alcoholism within 2 year prior dose ; drink≥12 time within 3 month prior dose ; alcohol test positive screening； 3 . Has history drug misuse within 2 year prior dose ; urine drug screen positive； 4 . Has history take product tobacco nicotine 5 cigarettes/day within 1 month prior dose , stop smoking study； 5 . Donated blood use another investigational drug within 3 month prior dosing； 6 . Has history chronic liver , renal , cardiovascular , neurological psychiatric , gastrointestinal , pulmonary , urinary , endocrine disease control drugs； 7 . Use drug affect function liver metabolism enzyme within 30 day prior dose ; need take medication may affect PK profile investigational drug ( include : product contain Calcium , aluminum , magnesium , iron zinc , sucralfate , antacid , nutrition supplement , Vitamins metal supplement ) study； 8 . Is take antibacterial agent prophylaxis treatment drugs； 9 . HIVAb , HBsAg , HCVAb syphilis RPR positive； 10 . Clinical significant abnormal 12lead electrocardiogram ( ECGs ) screening ( eg . atrioventricular block , torsades de pointes ventricular tachycardia ( TdT ) , type ventricular tachycardia , ventricular fibrillation , ventricular flutter , T wave change clinical significance QTc &gt; 450ms ) ； 11 . Has abnormal result laboratory test clinical significance assess investigator screening； 12 . Has gastrointestinal disease malabsorption syndrome affect drug Absorb； 13 . Has history seizures central nervous system disease investigator considers interfere compliancy protocol ; risk suicide； 14 . Has antibacterial , glucocorticoid , immunosuppressive agent drug may damage organ within 14 day prior dosing； 15 . Can orally take drug； 16 . Has history currently disease condition may affect safety efficancy assessment investigational drug judge investigator； 17 . Is member clinical site personnel directly affiliate study； 18 . Conditions investigator consider suitable enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>